优化转移性黑色素瘤的向治疗:使用恩科拉费尼布和特拉美提尼布组合,超出标准方案

François Pélouard1, Valérie Chedru-Legros2, Catherine Nganoa3

  • 1Dermatology Department, Caen University Hospital. francoispelouard@gmail.com.

Dermatology reports
|April 16, 2025
PubMed
概括

一种新的BRAF和MEK抑制剂组合,encorafenib-trametinib,在转移性黑色素瘤患者中表现出极好的耐受性和完全的瘤反应. 这种非标准的向治疗方法为那些经历了标准治疗的严重不良事件的患者提供了一个有希望的替代方案.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K